NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it is expected to be added to the Nasdaq Biotechnology Index (“NBI”) (Nasdaq: NBI). Immuneering’s addition will become effective prior to market open on Monday, December 22, 2025. The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market that are issued by c ...

Core Insights - Immuneering Corporation reported an extraordinary 86% overall survival rate at 9 months for first-line pancreatic cancer patients treated with atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) [1][3] - The company raised a total of $225 million in financing, which includes a $25 million private placement with Sanofi, extending its cash runway into 2029 [1][2][3] - Immuneering received a U.S. composition of matter patent for atebimetinib, expected to provide exclusivity until 2042 [1][5] Clinical Developments - The Phase 2a trial of atebimetinib + mGnP showed a favorable tolerability profile with only two Grade 3 adverse events (neutropenia and anemia) observed in over 10% of patients [3] - New case studies highlighted patients achieving significant responses, including one with a complete response and another who could proceed to radiation and surgery with curative intent [4][5] - Immuneering plans to report updated survival data in the first half of 2026 and begin dosing patients in a pivotal Phase 3 trial by mid-2026 [6][8] Financial Performance - As of September 30, 2025, the company reported cash and cash equivalents of $227.6 million, a significant increase from $36.1 million at the end of 2024 [8] - Research and development expenses for Q3 2025 were $10.9 million, slightly down from $11.3 million in Q3 2024, while general and administrative expenses increased to $4.5 million from $4.0 million [9][10] - The net loss for Q3 2025 was $15.0 million, or $0.38 per share, compared to a net loss of $14.6 million, or $0.49 per share, in Q3 2024 [11][20] Future Milestones - Near-term milestones include receiving regulatory feedback and preparing to begin dosing patients in the pivotal trial of atebimetinib + mGnP [6] - The company anticipates reporting updated circulating tumor DNA data at a major scientific meeting in Q2 2026 [6] - Immuneering is also planning to dose the first patient in a trial of atebimetinib in combination with Libtayo for non-small cell lung cancer in the second half of 2026 [7]

Core Insights - Immuneering Corporation will report its third quarter 2025 financial results and share case studies from a Phase 2a study of atebimetinib in combination with FOLFIRINOX for first-line pancreatic cancer patients on November 12, 2025 [1] Company Overview - Immuneering is a clinical-stage oncology company focused on developing a new category of cancer medicines known as Deep Cyclic Inhibitors [3] - The lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK aimed at improving durability and tolerability for MAPK pathway-driven tumors, including pancreatic cancers [3] - Currently, atebimetinib is in a Phase 2a trial targeting advanced solid tumors, including pancreatic cancer [3]

Core Insights - Immuneering Corporation announced a conference call to discuss updated overall survival and safety data for first-line pancreatic cancer patients treated with atebimetinib + mGnP, with a median follow-up of 9 months [1][2] Company Overview - Immuneering is a clinical-stage oncology company focused on developing Deep Cyclic Inhibitors, with its lead product candidate, atebimetinib, designed to improve durability and tolerability for MAPK pathway-driven tumors, including pancreatic cancer [4] - The company is currently conducting a Phase 2a trial for atebimetinib in patients with advanced solid tumors, including pancreatic cancer [4] Upcoming Events - The updated results will be highlighted in a poster presentation at the Pancreatic Cancer Action Network Scientific Summit 2025 and discussed during the conference call [2]

Core Viewpoint - Immuneering Corporation has appointed Dr. Thomas J. Schall as Chairman of the Board of Directors, which is seen as a strategic move to advance the company's oncology programs, particularly the lead product candidate, atebimetinib [1][4]. Company Overview - Immuneering is a clinical-stage oncology company focused on developing a new category of cancer medicines known as Deep Cyclic Inhibitors. The lead product candidate, atebimetinib, is designed to improve durability and tolerability for patients with MAPK pathway-driven tumors, including pancreatic cancer [5]. Leadership Background - Dr. Schall has over 30 years of experience in drug discovery and development, previously serving as the founder and CEO of ChemoCentryx, where he led the development of Tavneos®, a therapy for ANCA-associated vasculitis. ChemoCentryx was acquired by Amgen in 2022 for nearly $4 billion [2][4]. Strategic Importance - The appointment of Dr. Schall is considered pivotal as Immuneering prepares for late-stage development, regulatory filings, and commercialization of its therapies. His expertise in navigating the complex path from early science to market is expected to be critical for the company's success [3][4]. Upcoming Developments - Immuneering plans to announce updated data from its ongoing phase 2a study of atebimetinib in pancreatic cancer patients on September 25, with further presentations at the Pancreatic Cancer Action Network Annual Scientific Summit on September 28 [3].

Core Insights - Immuneering Corporation plans to announce updated overall survival data for first-line pancreatic cancer patients treated with atebimetinib + mGnP on September 25, 2025, following a 9-month median follow-up [1][3][6] - The company has reported a 94% overall survival (OS) rate at 6 months for patients treated with atebimetinib + mGnP, compared to 67% OS for standard care, which drops to approximately 47% by 9 months [3][6] - Immuneering is developing a new category of cancer medicines called Deep Cyclic Inhibitors, with atebimetinib being the lead candidate currently in a Phase 2a trial [4][6] Company Plans and Presentations - An investor call is scheduled for 8 a.m. ET on September 25, 2025, to discuss the updated data [1][6] - Immuneering will present a poster on "Atebimetinib + mGnP: Overall Survival and Safety in First Line Pancreatic Cancer Patients" at the PanCAN Scientific Summit on September 28, 2025 [6] - The company will also present preclinical data on Deep Cyclic Inhibitors at the 7th RAS-Targeted Drug Development Summit on September 17, 2025 [5][6]

Core Viewpoint - Immuneering Corporation has announced a clinical supply agreement with Eli Lilly for the evaluation of atebimetinib in combination with olomorasib in a Phase 2 trial targeting advanced non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations [1][2] Group 1: Clinical Development - The agreement supports the evaluation of Immuneering's lead product candidate, atebimetinib, a novel dual MEK inhibitor, in combination with olomorasib [1] - Immuneering is also evaluating atebimetinib in combination with Regeneron's anti-PD-1 therapy Libtayo in advanced NSCLC patients [1] - The combination aims to provide a vertical blockade of the RAS-MAPK pathway, potentially improving treatment outcomes in patients with limited options [3] Group 2: Product and Pipeline - Immuneering maintains global development and commercialization rights to atebimetinib [4] - The company is developing Deep Cyclic Inhibitors, with atebimetinib designed to improve durability and tolerability for MAPK pathway-driven tumors [5] - Atebimetinib is currently in a Phase 2a trial for advanced solid tumors, including pancreatic cancer [5]

Core Insights - Immuneering Corporation has entered into a definitive securities purchase agreement for a private placement expected to yield approximately $25 million in gross proceeds before fees and expenses [1] - The company is focused on developing a new category of cancer medicines called Deep Cyclic Inhibitors, with its lead product candidate, atebimetinib, currently in a Phase 2a trial for pancreatic cancer [2][5] - The recent data from the Phase 2a trial shows a 94% overall survival rate at 6 months for patients treated with atebimetinib in combination with mGnP, significantly higher than the 67% observed in the standard of care [2] Financing Details - The private placement involves the sale of 6,329,113 unregistered shares of Class A common stock at a price of $3.95 per share, representing a 15% premium over the last reported closing price [2] - Investors will also receive purchase warrants for an aggregate of 2,848,096 shares at an exercise price of $5.50 per share, with a five-year exercisability period following registration for resale [2] Company Overview - Immuneering is a clinical-stage oncology company dedicated to improving the survival of cancer patients through innovative treatments [5] - The company is developing atebimetinib as an oral, once-daily treatment aimed at enhancing durability and tolerability for MAPK pathway-driven tumors, including pancreatic cancers [5]